Comparative Analysis of Postoperative Radiotherapy Dose Escalation in Oral Cavity Cancer Patients with Positive Margins: A Propensity Score-Matched Study

被引:0
作者
Sarawagi, Rashmi [1 ]
Padmanabhan, Aravind [1 ]
Prajapati, Raju [2 ]
Gupta, Manish [1 ]
Das, Saikat [1 ]
Kharade, Vipin [1 ]
Tiwari, Arnav [3 ]
Reddy, B. Srinivas [1 ]
Shrivastava, Neelesh [4 ]
Pasricha, Rajesh [1 ]
机构
[1] All India Inst Med Sci, Dept Radiat Oncol, Bhopal 462026, Madhya Pradesh, India
[2] Sukh Sagar Med Coll & Hosp, Dept Radiat Oncol, Jabalpur, Madhya Pradesh, India
[3] Postgrad Inst Med Educ & Res, Dept Radiat Oncol, Chandigarh, India
[4] All India Inst Med Sci, Dept Surg Oncol, Bhopal, Madhya Pradesh, India
关键词
oral cavity squamous cell carcinoma; radiotherapy; positive margin; negative margin; postoperative; SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; ADVANCED HEAD; NECK-CANCER; CHEMOTHERAPY; TIME; IRRADIATION; CRITERIA; TRIAL; RTOG;
D O I
10.1055/s-0045-1802626
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction This study aimed to determine the impact of postoperative (PO) radiotherapy (RT) dose escalation in oral cavity squamous cell carcinoma (OCSCC) patients with positive margin (PM) in terms of local control (LC), duration of RT interruption, and toxicity in a tertiary care center. Materials and Methods Patients with OCSCC who were candidates for adjuvant RT were categorized into PM and negative margin (NM) arms depending on the margin status as per the histopathology report retrospectively. PM and NM patients received a total dose of 66 Gy to the site of the PM and 60 Gy for the NM. LC, acute and chronic toxicities, and duration of RT interruption were evaluated. Results A total of 56 patients were included in the study, of whom 39 had NM and 17 had PM. After propensity score matching, 11 patients were matched in each arm. The mean duration of RT treatment in the PM and NM arms were 49.5 days (standard deviation [SD] = 5.4) and 50.7 days (SD = 10.15) ( p = 0.3), with mean interruptions of 3.9 days (SD = 3.9) and 3.8 days (SD = 6.2), respectively ( p = 0.39). LC was 72.7% in the PM arm and 81.8% in the NM arm ( p = 0.6). Acute and chronic toxicities were comparable between the two arms. Conclusion Dose escalation to 66 Gy for PM during adjuvant RT for PO OCSCC can be used as an alternative strategy to reresection, especially in patients who have poor performance status, who have negative consent for surgery, and who have more than one adverse prognostic factor with comparable LC and toxicity as in the NM. However, further prospective studies are needed to establish its role as an alternative, which is highly unlikely in modern oncology practice, as PM patients are rarely seen in clinics currently with good surgical oncology practices. Abstract Rajesh Pasricha Introduction This study aimed to determine the impact of postoperative (PO) radiotherapy (RT) dose escalation in oral cavity squamous cell carcinoma (OCSCC) patients with positive margin (PM) in terms of local control (LC), duration of RT interruption, and toxicity in a tertiary care center. Materials and Methods Patients with OCSCC who were candidates for adjuvant RT were categorized into PM and negative margin (NM) arms depending on the margin status as per the histopathology report retrospectively. PM and NM patients received a total dose of 66 Gy to the site of the PM and 60 Gy for the NM. LC, acute and chronic toxicities, and duration of RT interruption were evaluated. Results A total of 56 patients were included in the study, of whom 39 had NM and 17 had PM. After propensity score matching, 11 patients were matched in each arm. The mean duration of RT treatment in the PM and NM arms were 49.5 days (standard deviation [SD] = 5.4) and 50.7 days (SD = 10.15) ( p = 0.3), with mean interruptions of 3.9 days (SD = 3.9) and 3.8 days (SD = 6.2), respectively ( p = 0.39). LC was 72.7% in the PM arm and 81.8% in the NM arm ( p = 0.6). Acute and chronic toxicities were comparable between the two arms. Conclusion Dose escalation to 66 Gy for PM during adjuvant RT for PO OCSCC can be used as an alternative strategy to reresection, especially in patients who have poor performance status, who have negative consent for surgery, and who have more than one adverse prognostic factor with comparable LC and toxicity as in the NM. However, further prospective studies are needed to establish its role as an alternative, which is highly unlikely in modern oncology practice, as PM patients are rarely seen in clinics currently with good surgical oncology practices. Abstract Rajesh Pasricha Introduction This study aimed to determine the impact of postoperative (PO) radiotherapy (RT) dose escalation in oral cavity squamous cell carcinoma (OCSCC) patients with positive margin (PM) in terms of local control (LC), duration of RT interruption, and toxicity in a tertiary care center. Materials and Methods Patients with OCSCC who were candidates for adjuvant RT were categorized into PM and negative margin (NM) arms depending on the margin status as per the histopathology report retrospectively. PM and NM patients received a total dose of 66 Gy to the site of the PM and 60 Gy for the NM. LC, acute and chronic toxicities, and duration of RT interruption were evaluated. Results A total of 56 patients were included in the study, of whom 39 had NM and 17 had PM. After propensity score matching, 11 patients were matched in each arm. The mean duration of RT treatment in the PM and NM arms were 49.5 days (standard deviation [SD] = 5.4) and 50.7 days (SD = 10.15) ( p = 0.3), with mean interruptions of 3.9 days (SD = 3.9) and 3.8 days (SD = 6.2), respectively ( p = 0.39). LC was 72.7% in the PM arm and 81.8% in the NM arm ( p = 0.6). Acute and chronic toxicities were comparable between the two arms. Conclusion Dose escalation to 66 Gy for PM during adjuvant RT for PO OCSCC can be used as an alternative strategy to reresection, especially in patients who have poor performance status, who have negative consent for surgery, and who have more than one adverse prognostic factor with comparable LC and toxicity as in the NM. However, further prospective studies are needed to establish its role as an alternative, which is highly unlikely in modern oncology practice, as PM patients are rarely seen in clinics currently with good surgical oncology practices. Abstract Rajesh Pasricha Introduction This study aimed to determine the impact of postoperative (PO) radiotherapy (RT) dose escalation in oral cavity squamous cell carcinoma (OCSCC) patients with positive margin (PM) in terms of local control (LC), duration of RT interruption, and toxicity in a tertiary care center. Materials and Methods Patients with OCSCC who were candidates for adjuvant RT were categorized into PM and negative margin (NM) arms depending on the margin status as per the histopathology report retrospectively. PM and NM patients received a total dose of 66 Gy to the site of the PM and 60 Gy for the NM. LC, acute and chronic toxicities, and duration of RT interruption were evaluated. Results A total of 56 patients were included in the study, of whom 39 had NM and 17 had PM. After propensity score matching, 11 patients were matched in each arm. The mean duration of RT treatment in the PM and NM arms were 49.5 days (standard deviation [SD] = 5.4) and 50.7 days (SD = 10.15) ( p = 0.3), with mean interruptions of 3.9 days (SD = 3.9) and 3.8 days (SD = 6.2), respectively ( p = 0.39). LC was 72.7% in the PM arm and 81.8% in the NM arm ( p = 0.6). Acute and chronic toxicities were comparable between the two arms. Conclusion Dose escalation to 66 Gy for PM during adjuvant RT for PO OCSCC can be used as an alternative strategy to reresection, especially in patients who have poor performance status, who have negative consent for surgery, and who have more than one adverse prognostic factor with comparable LC and toxicity as in the NM. However, further prospective studies are needed to establish its role as an alternative, which is highly unlikely in modern oncology practice, as PM patients are rarely seen in clinics currently with good surgical oncology practices.
引用
收藏
页数:5
相关论文
共 23 条
  • [1] [Anonymous], Textbook of Radiotherapy | Radiology Internet
  • [2] Examining adjuvant radiation dose in head and neck squamous cell carcinoma
    Avkshtol, Vladimir
    Handorf, Elizabeth A.
    Ridge, John A.
    Leachman, Brooke K.
    Liu, Jeffrey C.
    Bauman, Jessica
    Galloway, Thomas J.
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (07): : 2133 - 2142
  • [3] Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
    Bernier, J
    Domenge, C
    Ozsahin, M
    Matuszewska, K
    Lefèbvre, JL
    Greiner, RH
    Giralt, J
    Maingon, P
    Rolland, F
    Bolla, M
    Cognetti, F
    Bourhis, J
    Kirkpatrick, A
    van Glabbeke, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) : 1945 - 1952
  • [4] Long-term Follow-up of the RTOG 9501/Intergroup Phase III Trial: Postoperative Concurrent Radiation Therapy and Chemotherapy in High-Risk Squamous Cell Carcinoma of the Head and Neck
    Cooper, Jay S.
    Zhang, Qiang
    Pajak, Thomas F.
    Forastiere, Arlene A.
    Jacobs, John
    Saxman, Scott B.
    Kish, Julie A.
    Kim, Harold E.
    Cmelak, Anthony J.
    Rotman, Marvin
    Lustig, Robert
    Ensley, John F.
    Thorstad, Wade
    Schultz, Christopher J.
    Yom, Sue S.
    Ang, K. Kian
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (05): : 1198 - 1205
  • [5] Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck
    Cooper, JS
    Pajak, TF
    Forastiere, AA
    Jacobs, J
    Campbell, BH
    Saxman, SB
    Kish, JA
    Kim, HE
    Cmelak, AJ
    Rotman, M
    Machtay, M
    Ensley, JF
    Chao, KSC
    Schultz, CJ
    Lee, N
    Fu, KK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) : 1937 - 1944
  • [6] TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC)
    COX, JD
    STETZ, J
    PAJAK, TF
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05): : 1341 - 1346
  • [7] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [8] Target delineation for postoperative treatment of head and neck cancer
    Evans, Mererid
    Beasley, Matthew
    [J]. ORAL ONCOLOGY, 2018, 86 : 288 - 295
  • [9] Gokavarapu S, 2015, BRIT J ORAL MAX SURG, V53, P875, DOI [10.1016/J.bjoms.2015.08.257, 10.1016/j.bjoms.2015.08.257]
  • [10] Association of Treatment Delays With Survival for PatientsWith Head and Neck Cancer A Systematic Review
    Graboyes, Evan M.
    Kompelli, Anvesh R.
    Neskey, David M.
    Brennan, Emily
    Shaun Nguyen
    Sterba, Katherine R.
    Warren, GrahamW.
    Hughes-Halbert, Chanita
    Nussenbaum, Brian
    Day, Terry A.
    [J]. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2019, 145 (02) : 166 - 177